Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
We are applying our Cabaletta Approach to B cell Ablation (CABA®) platform to develop T cell therapies to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses.
How We Target Autoimmune Disease
A “cabaletta” is a rapid, repetitive, and technically challenging section of an operatic aria, designed to showcase the skills of the lead singer. Analogously, Cabaletta Bio strives to achieve rapid and repetitive product development in a broad set of indications to maximize the opportunity for patients with autoimmune diseases to have a potentially curative option that may eliminate the need for long-term immunosuppression.
